Document:

Patent License Agreement

 Exhibit 10.2 
 Execution Version 
 PATENT LICENSE AGREEMENT 
 PATENT LICENSE AGREEMENT (“Agreement”), dated January 20, 2009 (the “Effective Date”), by and between PANACOS
PHARMACEUTICALS, INC., a Delaware corporation (“Panacos”), and MYRIAD PHARMACEUTICALS, INC., a Delaware corporation (“Myriad”). Panacos and Myriad are referred to collectively herein as the “Parties” and
each, individually as a “Party.” 
 WHEREAS, pursuant to an Asset Purchase Agreement dated as of January 20, 2009, by and
between Panacos and Myriad (“Purchase Agreement”), Myriad acquired certain assets from Panacos used or which Myriad intends to use in connection with the development (preclinical and clinical), manufacture and commercialization of
3-O-(3’,3’-dimethylsuccinyl) betulinic acid and salts and solvates thereof, and polymorphs thereof (“Bevirimat”); 
 WHEREAS, the assets acquired by Myriad under the Purchase Agreement include all of Panacos’s interest in and to the Bevirimat Patents (as hereinafter defined), and the assets retained by Panacos under the Purchase Agreement include the
Panacos Patents (as hereinafter defined); 
 WHEREAS, Myriad has agreed to grant certain licenses to Panacos and its Affiliates under the
Bevirimat Patents; and 
 WHEREAS, Panacos has agreed to grant certain licenses to Myriad and its Affiliates under the Panacos Patents.

 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements set forth herein, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereto agree as follows: 
 Section 1. DEFINITIONS 
 1.1 The following terms, when used in this Agreement, shall have the respective meanings ascribed to them below: 
 (a) “Affiliate” means any corporation, firm, partnership, or other entity that, directly or indirectly, controls, is controlled by, or is
under common control with a Party. For purposes of this definition, “control” shall mean the ownership of at least fifty percent (50%) of the voting share capital of such entity or any comparable equity or ownership interest.

 (b) “Bevirimat Patents” shall mean the patents and patent applications identified on Exhibit A hereto. 
 (c) “Panacos Patents” shall mean the patents and patent applications identified on Exhibit B hereto. 

 (d) “Person” means an individual, a corporation, a limited liability company, a
partnership, an association, a trust or other entity or organization, including a federal, state, local or foreign government or regulatory entity or political subdivision or an agency or instrumentality thereof. 
 (e) “Product Operations” means the development (preclinical and clinical), manufacture, marketing, distribution, sale, or any other
exploitation of or activity with respect to, Bevirimat. 
 1.2 Unless otherwise defined in Section 1.1 or herein, each capitalized term
used in this Agreement that is defined in the Purchase Agreement shall have the meaning specified for such term in the Purchase Agreement. 
 Section 2. LICENSES 
 2.1 License to Myriad Under the Panacos Patents. Panacos hereby grants to Myriad and its
Affiliates an exclusive, perpetual worldwide, royalty-free, transferable (subject to Section 9.4) license, with the right to grant sublicenses to others under the Panacos Patents to develop, manufacture, make and have made, offer to sell, sell,
import, distribute, promote and use Bevirimat. 
 2.2 Sublicensees of Myriad. Any sublicensee of Myriad or its Affiliates permitted
under Section 2.1 shall be bound by the terms of this Agreement, and any such sublicense shall not relieve Myriad or its Affiliates of their obligations or liabilities under this Agreement. 
 2.3 License to Panacos Under the Bevirimat Patents. Myriad hereby grants to Panacos and its Affiliates a non-exclusive, perpetual, worldwide,
royalty-free, transferable (subject to Section 9.4) license, with the right to grant sublicenses to others in support of or ancillary to the business of Panacos or its Affiliates (i) under the Bevirimat Patents to manufacture, make and
have made, and use Bevirimat solely as an intermediate in the synthesis of maturation inhibitors other than Bevirimat, and (ii) under all claims set forth in United States Patent Number 5,679,828 and its foreign equivalents relating to
compounds other than Bevirimat to develop, manufacture, make and have made, offer to sell, sell, import, distribute, promote and use all maturation inhibitors other than Bevirimat. 
 2.4 Sublicensees of Panacos. Any sublicensee of Panacos or its Affiliates permitted under Section 2.3 shall be bound by the terms of this
Agreement, and any such sublicense shall not relieve Panacos or its Affiliates of their obligations or liabilities under this Agreement. 
 2.5 Duration of Licenses. Unless this Agreement is earlier terminated pursuant to the terms of Section 8.2 of this Agreement, the license granted under any Panacos Patent pursuant to Section 2.1 or any Bevirimat Patent
pursuant to Section 2.3 shall extend for the life of the particular patent involved. Any sublicense granted to any Panacos Patent pursuant to Section 2.1 or any Bevirimat Patent pursuant to Section 2.3 shall terminate in accordance
with the termination of the applicable license under Section 2.1 or 2.3, as the case may be. 
  

 2 

 2.6 Preservation of Rights. Any sale, assignment, license, sublicense, disposition, grant of a
lien or other security interest in, or transaction (i) by Panacos or any of its Affiliates affecting the Panacos Patents, or (ii) by Myriad or any of its Affiliates affecting the Bevirimat Patents, shall not affect and shall at all times
be subject to the rights of the other Party and its Affiliates under this Agreement. In addition, to the extent permitted by applicable law, in the event that a Party becomes insolvent, files a petition in bankruptcy, has such a petition filed
against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy (a “Filing Party”), such Filing Party shall immediately notify the other Party in
writing, and the other Party shall have the right but not the obligation, if the Filing Party remains insolvent or any such petition is not resolved within three (3) months after the date it is filed, to (i) immediately terminate this
Agreement, in whole or in part as the other Party may determine, upon written notice to the Filing Party; or (ii) assume responsibilities for the prosecution or maintenance of any patents or patent applications licensed to it by the Filing
Party. 
 2.7 Affiliates. With respect to the grant of any license to or the exercise of any right by an Affiliate of a Party, the
Party shall: (i) cause the Affiliate to be bound by the terms and conditions of this Agreement; and (ii) be responsible for the performance by the Affiliate of the obligations under this Agreement. 
 Section 3. CONSIDERATION 
 3.1 The licenses
granted under this Agreement are on a royalty free basis without compensation from a Party to any other Party. 
 Section 4. OWNERSHIP RIGHTS 

 4.1 All property rights in or related to the patents and patent applications licensed hereunder are and will remain the exclusive property
of the applicable owner, and, as between the Parties shall not be subject to challenge with respect to such ownership. 
 Section 5. PROSECUTION AND
MAINTENANCE OF PATENT RIGHTS 
 5.1 Responsibility. Subject at all times to Section 5.2, Panacos shall be solely responsible
for the prosecution, maintenance and renewal of the Panacos Patents, including the payment of all fees and expenses in connection therewith, and Myriad shall be solely responsible for the prosecution, maintenance and renewal of the Bevirimat
Patents, including the payment of all fees and expenses in connection therewith. Panacos will provide Myriad with copies of all documents exchanged with the relevant patent offices concerning the Panacos Patents, and Myriad will provide Panacos with
copies of all documents exchanged with the relevant patent offices concerning the Bevirimat Patents. 
 5.2 Abandonment of Patents.
Panacos shall have the right to unilaterally abandon any Panacos Patent, and Myriad shall have the right to unilaterally abandon any Bevirimat Patents, provided at least ninety (90) days prior to the renewal date or other date for loss or
abandonment of any such patent or patent application that a Party wishes to abandon, the owning Party gives notice to the other Party of its intent to abandon. If the other Party does not want such patent or patent application to become abandoned,
the other Party 

  

 3 

 
shall have the option to acquire the rights in said patent or patent application by: (i) giving written notice to the Party desiring to abandon the
patent or patent application within sixty (60) days following the delivery of the original notice; and (ii) paying the renewal or maintenance fees that are then due or taking such other action as may be necessary to prevent the loss or
abandonment, provided that, in the case of Panacos, such option shall only apply to United States Patent Number 5,679,828 and its foreign equivalents. In connection with the foregoing, the owning Party shall promptly provide the other Party
all information reasonably requested by the other Party regarding such patent or patent application. If the other Party does not exercise its option within the sixty (60) day period, the patent or patent application may be abandoned by its
owner. If the other Party exercises its option, the owning Party shall promptly execute such documents and take such other actions as may be reasonably necessary to accomplish the transfer of ownership. Following the transfer of ownership, the
patent or patent application so transferred shall no longer be deemed to be included within the scope of this Agreement, and the former owner shall have no further rights under this Agreement with respect thereto. Notwithstanding the foregoing, the
Party owning a pending patent application included with the Panacos Patents or the Bevirimat Patents, as the case may be, may abandon the application without such notice if the application has been finally rejected in the patent office where it is
pending (without resorting to appeals within the patent office), provided that in the event that the Party abandoning such a pending patent application does not file a continuation, continuation-in-part, divisional, or other application
claiming priority to such abandoned application, then such notice shall be required. For those patents or patent applications that the owning Party elects to abandon and are not acquired by the other Party, the owning Party may effect the
abandonment in due course. 
 5.3 Cooperation. Each Party shall reasonably cooperate with the other in the preparation, filing,
prosecution and maintenance of the patents and patent applications included with in the Panacos Patents and the Bevirimat Patents and shall not knowingly take a position in the prosecution of such patents that would materially adversely effect the
other Party. Each Party shall bear its own costs in connection with its cooperation. 
 Section 6. ENFORCEMENT OF PATENT RIGHTS 
 6.1 Notification. In the event that either Party becomes aware of actual or threatened infringement of any of the Panacos Patents or the Bevirimat
Patents by a third party anywhere in the world, that Party shall promptly notify the other Party in writing. 
 6.2 Enforcement.
Myriad shall have the sole and exclusive right, but not the obligation, to enforce the Bevirimat Patents. Panacos shall have the sole and exclusive right, but not the obligation, to enforce the Panacos Patents. If, within three (3) months of
Panacos receiving notice from Myriad of a third party’s probable infringement of the Panacos Patents within Myriad’s licensed field or Myriad receiving notice from Panacos of a third party’s probable infringement of the Bevirimat
Patents within Panacos’s licensed field, the licensor Party fails to take reasonable action to enforce such patents against such third party in the subject field, then the licensee Party shall have the right to take whatever action it deems
appropriate in its own name or, if required by law, in the name of the licensor Party to enforce such patents in the subject field, at the licensee Party’s sole cost. All monies recovered upon the final 

  

 4 

 
judgment or settlement of such action shall be used first to reimburse each Party for its actual costs incurred to investigate and pursue the claims against
the infringement, and second in proportion to the damages incurred by each Party. The non-enforcing Party shall cause its employees, agents or consultants, at the sole expense of the enforcing Party, to take such actions as are reasonably necessary
or appropriate to enable the enforcing Party to enforce the Panacos Patents or the Bevirimat Patents, as the case may be. 
 Section 7.
REPRESENTATIONS AND WARRANTIES 
 7.1 Representations and Warranties. Each Party represents and warrants to the other Party that
(i) it has all requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder, (ii) the execution and delivery by it and of this Agreement and the performance by it of its obligations
hereunder have been duly and validly authorized by all necessary board action on the part of such Party and no other further authorization or consent of its board of directors is required, (ii) this Agreement has been duly executed and
delivered by it and, assuming this Agreement constitutes the legal, valid and binding obligation of such Party, this Agreement constitutes a legal, valid and binding obligation of Seller, enforceable against such Party in accordance with its
respective terms. 
 7.2 Limitation. Neither Party makes any representation or warranty to any other Party with respect to the
validity, enforceability, title or status of any patent or patent application licensed hereunder. 
 7.3 No Obligation. This Agreement
shall not create for any Party any obligation to disclose to another Party, maintain, register, prosecute, pay for, enforce or otherwise manage any patents or patent applications except as expressly set forth herein. 
 7.4 Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, ALL WARRANTIES, CONDITIONS, REPRESENTATIONS, INDEMNITIES AND GUARANTEES
WITH RESPECT TO THE PANACOS PATENTS OR THE BEVIRIMAT PATENTS, WHETHER EXPRESS OR IMPLIED, ARISING BY LAW, CUSTOM, PRIOR ORAL OR WRITTEN STATEMENTS BY, EITHER PARTY, THEIR AGENTS OR OTHERWISE (INCLUDING, BUT NOT LIMITED TO ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE AND NON-INFRINGEMENT) ARE HEREBY OVERRIDDEN, EXCLUDED AND DISCLAIMED. 
 Section 8. TERM AND
TERMINATION 
 8.1 Term. Subject to Sections 8.2 and 8.3, the term of this Agreement will commence on the Effective Date and
shall continue until the end of the life of the last patent licensed pursuant to Sections 2.1 and 2.3 of this Agreement. 
 8.2 Partial
Termination. Either Party may terminate the licenses granted by it under the terms of this Agreement upon thirty (30) days written notice to the other Party in the event of a material breach of any provision of this Agreement by the other
Party, unless such breach is cured within such thirty (30) day notice period. 
  

 5 

 8.3 Effect of Termination. Upon a termination of the licenses granted by a Party pursuant to
Section 8.2, the terminating party shall assume all rights and obligations of the non-terminating party with respect to any sublicenses granted pursuant to this Agreement, provided however that the terminating party’s rights and
obligations do not exceed those rights and obligations granted by it herein. For the avoidance of doubt, no termination or partial termination pursuant to Section 8.2 shall relieve a Party from liability for breach of this Agreement.

 Section 9. GENERAL PROVISIONS 
 9.1 No Agency. Nothing in this Agreement shall be deemed in any way or for any purpose to constitute any Party an agent or joint venturer of another unaffiliated party. 
 9.2 No Third Party Beneficiaries. This Agreement shall inure to the benefit of the Parties and their respective successors and permitted assigns.
Nothing contained in this Agreement, express or implied, is intended to or shall confer upon any Person other than the Parties any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 
 9.3 Entire Agreement. This Agreement, the Purchase Agreement and the Ancillary Agreements constitute the entire agreement between Panacos and
Myriad with respect to the subject matter hereof and thereof supersede any prior agreements or understandings between Panacos and Myriad and any representations or statements made by or on behalf of Panacos or any of its Affiliates to Myriad,
whether written or oral (other than the Confidentiality Agreement), with respect to the subject matter hereof and thereof. 
 9.4
Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. Neither Party may assign any of its rights or delegate any of its performance
obligations hereunder without the prior written approval of the other Party; provided, however, that either Party shall have the right to assign this Agreement or any of its rights hereunder without such approval at any time to any
Affiliate of such Party or to any Person to whom all or substantially all of such Party’s assets, or with respect to Myriad all or substantially all of Myriad’s assets related to Bevirimat, are transferred or in connection with a merger,
consolidation or other similar corporate transaction involving such Party, but only if, in the case of such a transfer of assets, such Affiliate or Person assumes this Agreement in writing and agrees to be bound by and to comply with the terms and
conditions hereof applicable to such assigning Party. Any purported assignment of rights or delegation of performance obligations in violation of this Section 9.4 is void. 
 9.5 Notices. All notices, requests, demands, claims and other communications hereunder shall be in writing. Any notice, request, demand, claim or
other communication hereunder shall be deemed duly given, made and received (i) when delivered personally or by facsimile, (ii) four (4) Business Days after it is sent by registered or certified mail, return receipt requested, postage
prepaid or (iii) one (1) Business Day after it is sent for next Business Day delivery via a reputable nationwide overnight courier service, in each case to the intended recipient as set forth below: 
 If to Myriad: 
 Myriad Pharmaceuticals, Inc. 
 320 Wakara Way 
 Salt Lake City, Utah 84108 
 Attention: President 
 Phone: 801-584-3631 
 Facsimile: 801-584-3640 
  

 6 

 Copy to: 
 Myriad Pharmaceuticals, Inc. 
 320 Wakara Way 
 Salt
Lake City, Utah 84108 
 Attention: Legal Department 
 If to
Panacos: 
 Panacos Pharmaceuticals, Inc. 
 Attention: Chief
Executive Officer 
 134 Coolidge Avenue 
 Watertown, MA 02472

 Facsimile: 617-923-2276 
 Telephone: 617-926-1551 

Copy to: 
 Skadden, Arps, Slate, Meagher &
Flom LLP 
 One Beacon Street 
 Boston, MA 02108 
 Attention: Kent A. Coit, Esq. 
 Phone: 617-573-4800 
 Facsimile: 617-573-4822 
 Any Party may give any notice, request, demand,
claim, or other communication hereunder using any other means (including personal delivery, expedited courier, messenger service, facsimile, ordinary mail, or electronic mail), but no such notice, request, demand, claim or other communication shall
be deemed to have been duly given unless and until it actually is received by the Party for whom it is intended. Any Party may change the address to which notices, requests, demands, claims and other communications hereunder are to be delivered by
giving the other Party notice in the manner herein set forth. 
  

 7 

 9.6 Amendments and Waivers. The Parties may mutually amend or waive any provision of this
Agreement at any time. No amendment or waiver of any provision of this Agreement shall be valid unless the same shall be in writing and signed, in the case of an amendment, by the Parties, or in the case of a waiver, by the Party against whom the
waiver is to be effective. No waiver by any Party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach
of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. 
 9.7
Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or
enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, Myriad and
Panacos agree that the body making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration or area of the term or provision, to delete specific words or phrases, or to replace any invalid or
unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified.

 9.8 Expenses. Except as otherwise specifically provided to the contrary in this Agreement, each of Myriad and Panacos shall bear
its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement and the transactions contemplated hereby. 
 9.9 Governing Law. This Agreement and any disputes hereunder shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule
(whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware. 
 9.10 Submission to Jurisdiction. Each of Myriad and Panacos consents and (a) submits to the exclusive jurisdiction of any state or federal court sitting in the State of Delaware, (b) agrees that all
claims in respect of any action or proceeding seeking to enforce any provision of, or based on any right arising out of, this Agreement may be heard and determined only in any such court, (c) waives any claim of inconvenient forum or other
challenge to venue in such court, and (d) agrees not to bring any action or proceeding arising out of or relating to this Agreement in any other court. Each of Myriad and Panacos may make service on the other Party, and each of Myriad and
Panacos agrees to accept service, of any summons, complaint or other initial pleading made in the manner provided for the giving of notices in Section 9.5. Nothing in this Section 9.10, however, shall affect the right of any Party to serve
such summons, complaint or initial pleading in any other manner permitted by law. 
  

 8 

 9.11 Construction. 
 (a) The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their intent, and no rule of strict construction shall be applied against any Party. 
 (b) Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated
thereunder, unless the context requires otherwise. 
 (c) The Section headings contained in this Agreement are inserted for convenience only
and shall not affect in any way the meaning or interpretation of this Agreement. 
 (d) Any reference herein to a Section or Exhibit shall be
deemed to refer to a Section or Exhibit of this Agreement, unless the context clearly indicates otherwise. 
 (e) Whenever the words
“include”, “includes” or “including” are used in this Agreement, they shall be deemed followed by the words “without limitation.” 
 9.12 Waiver of Jury Trial. TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH OF MYRIAD AND PANACOS HEREBY IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON
CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT. 
 9.13 Exhibits. Exhibits identified in this Agreement are incorporated herein by reference and made a part hereof. 
 9.14 Counterparts and Facsimile Signature. This Agreement may be executed in counterparts, each of which shall be deemed an original but which
together shall constitute one and the same instrument. This Agreement may be executed by facsimile signature. 
 [Signature Page Follows]

  

 9 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement under seal as of the date first above
written. 
  

			
	PANACOS PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Alan W. Dunton

	Name:	 	Alan W. Dunton M.D.
	Title:	 	President and Chief Executive Officer
	
	MYRIAD PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Adrian N. Hobden

	Name:	 	Adrian N. Hobden
	Title:	 	PresidentUNC/Niigata/Panacos License Agreement

 Exhibit 10.3 
 EXECUTION COPY 
 UNC/NIIGATA/PANACOS LICENSE AGREEMENT 
 UNC/NIIGATA/PANACOS LICENSE AGREEMENT (this “Agreement”), effective as of January 20, 2009 (the “Effective Date”), between THE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL having an address at CB #4105, 308 Bynum Hall, Chapel Hill, NC (hereinafter referred to as “University”), NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES having an address at 5-13-2
Kamishin’Ei-cho Niigata 950-2081, Japan (“Niigata”) and PANACOS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware and having an address at 209 Perry Parkway, Gaithersburg, MD 20877 (together with
its Affiliates hereinafter referred to as “Licensee”). 
 WITNESSETH 
 WHEREAS, University owns and controls its share of the ownership interest in the inventions covered by the Patents listed in Appendix A attached hereto
(“University Inventions”), developed jointly by University and Licensee pursuant to the Sponsored Research Agreement, and Niigata owns and controls its share of the ownership interest in the inventions covered by the Patent listed on
Appendix B attached hereto (“Niigata Inventions”) (University Inventions and Niigata Inventions hereinafter collectively referred to as “Inventions”); and 
 WHEREAS substantially concurrently with the execution and delivery of this Agreement, (i) Licensee and Myriad Genetics, Inc. (“Myriad”)
are entering into, and effecting a closing under, an Asset Purchase Agreement and related agreements whereby Panacos is assigning to Myriad Panacos’s share of the ownership interest in certain inventions covered by certain Patents (not
including the Inventions) jointly owned by Panacos and University (the “Bevirimat Patents”), and (ii) University and Myriad are entering into a License Agreement dated as of the date hereof whereby University is granting to Myriad a
worldwide license to the Bevirimat Patents; and 
 WHEREAS, Licensee is desirous of producing, using and selling products which include the
use of Inventions and is willing to expend its commercially reasonable efforts and resources to do so if it can obtain an exclusive license to use the Inventions under the terms and conditions set forth herein; and 
 WHEREAS, University and Niigata desire to facilitate a timely transfer of their information and technology concerning the Inventions for the ultimate
benefit of the public and this transfer is best accomplished by the grant of this license; and 
 WHEREAS, in the opinion of the University
and Niigata, this transfer can best be accomplished consistent with their mission by affiliation with Licensee; 
 WHEREAS, University,
Niigata, and Licensee entered into that certain License Agreement dated as of February 28, 2003 (as amended) pursuant to which Licensee obtained an exclusive license to certain Inventions (the “Original Agreement”); 

WHEREAS, University, Niigata, and Licensee now wish to amend and restate the Original Agreement in its entirety; 
  

 1 

 EXECUTION COPY 
  

 NOW, THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter
set forth, it is agreed by and between the parties as follows: 
 I. DEFINITIONS 
 1.1. “UNIVERSITY TECHNOLOGY” means any unpublished (a) research and development information,
(b) unpatented inventions, and (c) technical data, owned by or in the control of University prior to the Effective Date or during the Term of this Agreement, which relates to and is necessary for: (i) the practice of the Inventions,
or (ii) the manufacture, use, sale, offer for sale or importation of any compounds disclosed in the Patents or any analogs, derivatives, modifications or improvements thereof, and which University has the right to provide Licensee under this
Agreement, and which Licensee does not otherwise own or control. 
 1.2. “INVENTIONS” has the meaning
set forth in the first Whereas clause above. 
 1.3. “NIIGATA INVENTIONS” has the
meaning set forth in the first Whereas clause above. 
 1.4. “UNIVERSITY INVENTIONS”
has the meaning set forth in the first Whereas clause above. 
 1.5. “LICENSED
PRODUCTS” means (i) any method, procedure, or component part thereof whose manufacture, use, sale, offer for sale or importation is covered by any University Technology or Niigata Technology or by one or more Valid Claims of
the Patents, or (ii) any product containing at least one Licensed Compound. 
 1.6. “LICENSED
COMPOUNDS” means any individual compounds whose manufacture, use, sale, offer for sale or importation is covered by any University Technology or Niigata Technology or by one or more Valid Claims of the Patents. 
 1.7. “PATENTS” means any US patents and/or patent applications owned or controlled in whole or in part by
University or Niigata prior to or during the Term of this Agreement and which University and/or Niigata has the right to provide its share to Licensee and which are included in and limited to those listed in Appendix A and Appendix B, as well as any
continuations, continuations in part, divisionals, provisionals, continued prosecution applications, extensions, or reissues thereof, and any foreign counterpart of any of the foregoing. 
 1.8. “NET SALES” means, subject to Article 3.4, the invoiced sales price of Licensed Products sold
by Licensee, less (a) any charges for sales taxes or other taxes separately stated on the invoice, (b) shipping and insurance charges, (c) actual credits and allowances for returned, rejected, recalled, or defective goods,
(d) trade discounts, but before cash discounts and (e) government mandated rebates. Licensed Products will be considered sold when billed out, or when delivered or paid for before delivery, whichever first occurs. As used herein,
“cash discounts” means discounts given on account of payments made in cash or payments made early. 
  

 2 

 EXECUTION COPY 
  

 1.9. “LICENSED TERRITORY” means the world,
subject to any restrictions in Article XI herein. 
 1.10. “LICENSED FIELD” means any
and all human therapeutic and prophylactic uses. 
 1.11. “SUBLICENSEE” means any person or
organization to which Licensee has granted a sublicense to the University Technology or Niigata Technology or Patents for the purpose of development and/or commercialization of Licensed Products in the Licensed Field. 
 1.12. “CONFIDENTIAL INFORMATION” means information considered proprietary to the party disclosing
the information, and may include information relating to: research, development, patent prosecution and maintenance, manufacturing, purchasing, accounting, engineering, marketing, merchandising or selling. 
 1.13. “SUBLICENSE INCOME” means all royalties, all other payments, and any equity Licensee
receives from Sublicensees, of which University and/or Niigata is owed a percentage; provided, however, that Sublicense Income shall specifically exclude (i) payments made in consideration for the issuance of equity or debt securities of
Licensee at fair market value (but shall specifically include any payments received by Licensee from the issuance of securities of Licensee to the extent such payments are in excess of fair market value), (ii) equity or debt securities of a
Sublicensee issued to Licensee if acquired by Licensee at fair market value, and (iii) payments specifically committed to research funding or development activities, or reimbursements of the same. In the event of a sublicense as contemplated
herein, such sublicense shall state explicitly the consideration provided in exchange for University Technology or Niigata Technology or Patents. 
 1.14. “IND” means an Investigational New Drug Application filed with the Food and Drug Administration for authorization to initiate human clinical trials in the United States, or any foreign equivalent
document for authorization to initiate human clinical trials outside the United States. 
 1.15.
“AFFILIATE” means any corporation or other business entity which, directly or indirectly, controls, is controlled by, or is under common control with, a party. For purposes of this definition, “control” means
ownership or beneficial interest in 40% or more of the voting stock or other voting interest of the corporation or other business entity. 
 1.16. “ANDA” means an Abbreviated New Drug Application, made in the form of a Food and Drug Administration submission or package to the Food and Drug Administration, for approval to market a
Licensed Product in the United States, or any foreign equivalent document for approval to market a Licensed Product outside the United States. 
  

 3 

 EXECUTION COPY 
  

 1.17. “CLASS OF LICENSED
COMPOUNDS” means each subset of Licensed Compounds as described in the Patents and identified in Appendix A and Appendix B as (i) Class 1, (ii) Class 2, or (iii) Class 3. 
 1.18. “FIRST COMMERCIAL SALE” means the first sale of Licensed Product for use in
the Field by Licensee or its Sublicensee to any third party in a country. 
 1.19. “NDA” means an
original New Drug Application, made in the form of a Food and Drug Administration submission or package to the Food and Drug Administration, for approval to market a Licensed Product in the United States, or any foreign equivalent document.

 1.20. “PERFORMANCE MILESTONE” means any milestone listed on Appendix C attached
hereto. 
 1.21. “PHASE II CLINICAL TRIAL” means a
dosing range trial to evaluate efficacy and safety in the targeted patient population and/or to define optimal dosing regimen of Licensed Product, or any other trial required to be designated as a Phase II clinical trial by the Food and Drug
Administration. 
 1.22. “ROYALTY QUARTER” has the meaning set forth in Article 3.5.

 1.23. “SPONSORED RESEARCH AGREEMENT” means that certain sponsored
research agreement by and between University and Licensee effective April 28, 1999, including any amendments thereto. 
 1.24. “TERM” shall commence on the Effective Date and shall expire upon the expiration of the last Valid Claim of the Patents, unless earlier terminated pursuant to Article VII. 
 1.25. “VALID CLAIM” means either (a) a claim of an issued and unexpired patent included
within the Patents which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has
not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise or (b) a claim of a pending patent application included within the Patents, which claim was filed in good faith and has not been abandoned or finally
disallowed without the possibility of appeal or refiling of said application. Notwithstanding the foregoing (and subject to Article 3.3(iii)), if a claim of a pending patent application has not issued as a claim of an issued patent within ten
(10) years after the filing date from which such claim takes priority, such pending claim shall cease to be a Valid Claim for purposes of this Agreement unless and until such claim becomes an issued claim of an issued patent. 
 1.26. “PATENT COUNSEL” has the meaning set forth in Article 11.1. 
  

 4 

 EXECUTION COPY 
  

 1.27. “NIIGATA TECHNOLOGY” means any
unpublished (a) research and development information, (b) unpatented inventions, and (c) technical data, owned by or in the control of Niigata prior to the Effective Date or thereafter during the Term, which relates to and is
necessary for: (i) the practice of the Niigata Inventions, or (ii) the manufacture, use, sale, offer for sale or importation of any compounds disclosed in the Niigata Patents or any analogs, derivatives, modifications or improvements
thereof, and which Niigata has the right to provide Licensee under this Agreement, and which Licensee does not otherwise own or control. 
 II. TERMINATION
OF ORIGINAL AGREEMENT; GRANT OF LICENSE; UNIVERSITY RESTRICTIONS 
 2.1. University, Niigata, and Licensee hereby acknowledge
and agree that the Original Agreement is terminated and superseded by this Agreement as of the Effective Date of this Agreement. Notwithstanding any provision to the contrary in the Original Agreement, no provision contained therein shall survive
termination of the Original Agreement. Notwithstanding the foregoing, each party hereby agrees that all actions, suits, damages, claims and demands, in law or in equity, which either of them has against the other under the terms of the Original
Agreement, upon, or by reason of any breach of the Original Agreement, shall be enforceable under this Agreement. 
 2.2. (i)
University grants to Licensee, to the extent of the Licensed Territory, a non-exclusive right and license (with the right to grant sublicenses pursuant to Article 2.3) to use University Technology in the Licensed Field, subject to all the terms and
conditions of this Agreement. 
 (ii) University grants to Licensee, to the extent of the Licensed Territory, an exclusive
right and license (with the right to grant sublicenses pursuant to Article 2.3) under the Patents to make, have made, use, sell, offer for sale, and import Licensed Products and Licensed Compounds embodying the Invention(s) in the Licensed Field,
upon the terms and conditions set forth herein. 
 (iii) Niigata grants to Licensee, to the extent of the Licensed Territory,
a non-exclusive right and license (with the right to grant sublicenses pursuant to Article 2.3) to use Niigata Technology in the Licensed Field, subject to all the terms and conditions of this Agreement. 
 (iv) Niigata grants to Licensee, to the extent of the Licensed Territory, an exclusive right and license (with the right to grant
sublicenses pursuant to Article 2.3) under the Niigata Patents to make, have made, use, sell, offer for sale, and import Licensed Products and Licensed Compounds embodying the Niigata Inventions in the Licensed Field, upon the terms and conditions
set forth herein. 
 2.3. University and Niigata each grant to Licensee, to the extent of the Licensed Territory, the right to
sublicense. Sublicensees shall be subject to provisions substantially similar to the following provisions of this Agreement: Articles 2.5, 2.6, 2.7, 2.8, 2.9, VI, IX, 11.6, XIV, XV, XVI, XIX, XXI, and XXII and this Article 2.3. Sublicensees may not
further sublicense 

  

 5 

 EXECUTION COPY 
  

 
any rights they obtain herein without the written consent of University as to the University Inventions and Niigata as to the Niigata Inventions. In the
event of early termination of this Agreement, any sublicense agreement with any Sublicensee shall provide for the termination of the sublicense, or the conversion to a license directly between such Sublicensee and University and/or Niigata (as the
case may be) on substantially the same terms as the sublicense agreement, at the option of the Sublicensee, provided, however, that in no event shall University or Niigata have greater obligations to such Sublicensee as it has to Licensee hereunder.

 2.4. Any license granted herein (excluding the grant in Article 2.2(i) above) is exclusive for the Term of this Agreement.

 2.5. Licensee shall not disclose any University Technology pursuant to Article 2.2(i) above to third parties during the
Term or any time thereafter, provided, however, that disclosure of University Technology may be made at any time (1) with the prior written consent of University, or (2) pursuant to the provisions of this Agreement, including Article 6
herein. 
 2.6. Licensee shall not disclose any Niigata Technology pursuant to Article 2.2(iii) above to third parties during
the Term or any time thereafter, provided, however, that disclosure of Niigata Technology may be made at any time (1) with the prior written consent of Niigata, or (2) pursuant to the provisions of this Agreement, including Article 6
herein. 
 2.7. Licensee is further granted the right to disclose and use any University Technology, or other Confidential
Information of University or Niigata Technology, or other Confidential Information of Niigata pertaining to the Patents, Licensed Products, or Licensed Compounds in any submission to local, state, federal or foreign governmental agency, including,
but not limited to, the US Food and Drug Administration and the US Patent and Trademark Office, notwithstanding any provisions to the contrary in Article VI. 
 2.8. Notwithstanding the foregoing, any and all licenses granted hereunder are subject to the rights of the United States Government which
may arise out of its sponsorship of the research which led to the Inventions. 
 2.9. Subject to the licenses granted to
Licensee pursuant to the foregoing provisions of this Article II, each party retains all right, title, and interest in such party’s inventions and intellectual property, including, without limitation, its share of any joint inventions and
jointly owned Patents. 
 III. LICENSE FEE AND ROYALTIES 
 3.1. [RESERVED]. 
 3.2. The parties acknowledge that Licensee has paid University for all
past costs (including reasonable attorney’s fees) arising out of the filing, prosecution, or maintenance of the Patents. Licensee will pay a further license fee in the form of 

  

 6 

 EXECUTION COPY 
  

 
payment of future costs (including attorney’s fees) arising out of the filing and prosecution of the Patents covering the Inventions pursuant to Article
XI of this Agreement. Payment of such costs shall be non-refundable and shall not be a credit against any other amounts due hereunder. 
 3.3. (i) Beginning on the Effective Date of this Agreement and continuing, on a country-by-country basis, until the last to expire Valid Claim of Patents covering such Licensed Products, Licensee will pay University a
running patent royalty on all Net Sales of Licensed Products in the Licensed Field covered by a Valid Claim of the Patents, in accordance with the chart below: 
  

				
	 NET SALES OF
 LICENSED PRODUCT(S)
	  	ROYALTY RATE	 
	 <$100 million
	  	2.5	%
	 >$100 million
	  	3	%

 Notwithstanding the foregoing provisions of
this Article 3.3(i), (a) in the event that the Licensed Product for which royalties are payable hereunder is covered by a Valid Claim of the Niigata Patents but no other Patents, then Licensee shall pay University one-half ( 1/2) of the royalties otherwise payable to University under this Article 3.3(i), and Licensee shall pay Niigata the remaining
one-half ( 1/2) of such royalties; and (b) in the event that the Licensed Product for which royalties are payable
hereunder is covered by Valid Claims of both the Niigata Patents and at least one other Patent, then Licensee shall pay University two-third ( 2/3) of the royalties otherwise payable to University under this Article 3.3(i), and Licensee shall pay Niigata the remaining one-third ( 1/3) of such royalties. 
 (ii) During
the Term of this Agreement, Licensee will pay University a running technology royalty on all Net Sales of Licensed Products in the Licensed Field not covered by a Valid Claim of the Patents but whose manufacture, use, sale, offer for sale or
importation is covered by University Technology, in accordance with the chart below: 
  

				
	 NET SALES OF
 LICENSED PRODUCT(S)
	  	ROYALTY RATE	 
	 <$100 million
	  	1.25	%
	 >$100 million
	  	1.5	%

 Notwithstanding the foregoing provisions of this Article 3.3(ii), (a) in the event that the
Licensed Product for which royalties are payable hereunder is covered by both University Technology and Niigata Technology, then Licensee shall pay University 

  

 7 

 EXECUTION COPY 
  

 
one-half ( 1/2) of the royalties
otherwise payable to University under this Article 3.3(ii), and Licensee shall pay Niigata the remaining one-half ( 1/2) of
such royalties; and (b) in the event that the Licensed Product for which royalties are payable hereunder is not covered by University Technology but is covered by Niigata Technology, then Licensee shall pay Niigata one hundred percent
(100%) of the royalties otherwise payable to University under this Article 3.3(ii). 
 (iii) In addition to
the foregoing, the parties acknowledge and agree that in the event a claim of a pending patent application ceases to be a Valid Claim pursuant to the last sentence of Article 1.23, and such pending patent application later issues during the Term of
this Agreement, Licensee shall pay University and/or Niigata the difference between any patent royalties that would have been payable by Licensee under Article 3.3(i) if such claim of the pending patent application had not ceased to be a Valid Claim
in the first instance pursuant to Article 1.23, and the technology royalty actually paid pursuant to Article 3.3(ii). 
 (iv)
No later than thirty (30) days before the First Commercial Sale of a particular Licensed Product, Licensee retains the right to notify University and Niigata in writing of its determination of the allocation of payments between University and
Niigata hereunder (if any). In such an event, University and Niigata shall have thirty (30) days to respond in writing if they disagree with Licensee’s determination. In the event Licensee does not receive written notice of a disagreement
within such 30 day period, then Licensee’s determination shall be deemed acceptable to the parties. In the event Licensee receives written notice of a disagreement within such 30 day period, Licensee retains the right to make royalty payments
into an escrow account until such time as University and Niigata provide Licensee with written confirmation of their resolution of such disagreement. In no event shall Licensee owe University and Niigata, in the aggregate, royalties greater than the
royalty rates set forth in this Article 3.3. 
 3.4. (i) In the event any Licensed Product in the Licensed Field is a
combination of one or more Licensed Compounds with one or more other active ingredients not licensed hereunder, Net Sales for purposes of determining royalty payments on such combination shall be calculated by multiplying the net sales
(i.e., the invoiced sales price of the combination less the deductions set forth in Article 1.6) by the fraction A/(A+B) in which “A” is the total of the gross selling prices of the Licensed Compounds, and “B” is the
total of the gross selling prices of the other active ingredients. 
 (ii) In the event that it is not possible to determine
the gross selling price for each ingredient, Net Sales shall be calculated by multiplying the net sales (i.e., the invoiced sales price of the combination less the deductions set forth in Article 1.6) of the combination by the fraction
C/(C+D), in which “C” is the total of the direct costs plus the direct overhead of the Licensed Compounds and “D” that of the other active ingredients. The direct costs plus the direct overhead of a component shall be determined
in accordance with generally acceptable cost accounting principles. 
  

 8 

 EXECUTION COPY 
  

 3.5. Beginning with the date of First Commercial Sale of any Licensed Product in the
Licensed Field, Licensee agrees to make quarterly written reports to University and Niigata (with respect to Licensed Products covered by a Valid Claim of the Niigata Patents or by Niigata Technology) within thirty (30) days after the first
(1st) days of each January, April, July, and October during the Term of this Agreement and as of such dates, stating in each such report the number, description, and aggregate Net Sales of Licensed Products sold, used, or otherwise disposed of
during the preceding three calendar months (each such three calendar months a “Royalty Quarter”) and upon which a royalty or percentage of Sublicense Income is payable as provided in Articles 3.3 or IV hereof, as appropriate. The first
such report shall include all Net Sales of Licensed Products made prior to the date of such report. Until Licensee has achieved the First Commercial Sale of Licensed Product, a report shall be submitted by Licensee at the end of each January after
the Effective Date of this Agreement and will include a full written report summarizing Licensee’s technical and other efforts made towards such First Commercial Sale of a Licensed Product. 
 3.6. In the event that it is necessary or required for Licensee to make royalty or other payments to one or more third parties in order
for Licensee or any Sublicensee to make, use, or sell Licensed Products, Licensee may offset a total of fifty percent (50%) of such third-party payments against any royalty payments and/or percentage of Sublicense Income, as appropriate and in
the Royalty Quarter they are due, that are otherwise due University and/or Niigata hereunder, provided that in no event shall the royalty payments or percentage of Sublicense Income otherwise due University and/or Niigata be reduced by more than
fifty percent (50%) in any Royalty Quarter. Notwithstanding the foregoing, in no event shall Licensee offset third-party payments against any royalty payments and/or percentage of Sublicense Income that are otherwise due University and/or
Niigata hereunder if such third party payments relate solely to other active ingredients to which the combination Product calculations in Article 3.4 have been applied. 
 3.7. Concurrently with the making of each report pursuant to Article 3.5 above, Licensee shall pay to the University and/or Niigata all
payments due University and/or Niigata under Articles 3.3, 3.8 or IV, as appropriate. 
 3.8. Licensee will make milestone
payments upon the first of either Licensee or a Sublicensee reaching the designated stages of development listed in the table below, for each Licensed Product. Payment shall be the greater of the compensation due University pursuant to Article IV
(if applicable), or the amount listed in the table below. 
 Notwithstanding the
foregoing, (a) in the event that the Licensed Product for which milestone payments are due hereunder is covered by a Valid Claim of the Niigata Patents but no other Patents, or is not covered by a Valid Claim of any Patents but is covered by
the University Technology and Niigata Technology, then Licensee shall pay University one-half ( 1/2) of the compensation
otherwise payable to University under this Article 3.8 (or Article IV as the case may be), and Licensee shall pay Niigata the remaining one-half ( 1/2) of such compensation; and (b) in the event that the Licensed Product for which milestone payments are due hereunder is covered by Valid Claims of both the Niigata Patents and at least one other Patent,
then Licensee shall pay University two-thirds ( 2/3) of the compensation otherwise payable to University under this Article
3.8 (or Article IV as 

  

 9 

 EXECUTION COPY 
  

 
the case may be), and Licensee shall pay Niigata the remaining one-third ( 1/3
) of such compensation; and (c) in the event that the Licensed Product for which milestone payments are due hereunder is not covered by a Valid Claim of any Patents but is covered by the Niigata
Technology but not the University Technology, then Licensee shall pay Niigata one hundred percent (100%) of the compensation otherwise payable to University under this Article 3.8 (or Article IV as the case may be). 
 No later than thirty (30) days before payments are due hereunder (or under Article IV as the case may be), Licensee retains the right to notify
University and Niigata in writing of its determination of the allocation of payments between University and Niigata hereunder (if any). In such an event, University and Niigata shall have thirty (30) days to respond in writing if they disagree
with Licensee’s determination. In the event Licensee does not receive written notice of a disagreement within such 30 day period, then Licensee’s determination shall be deemed acceptable to the parties. In the event Licensee receives
written notice of a disagreement within such 30 day period, Licensee retains the right to make milestone payments into an escrow account until such time as University and Niigata provide Licensee with written confirmation of their resolution of such
disagreement. In no event shall Licensee owe University and Niigata, in the aggregate, milestone payments greater than the amounts set forth in the table herein or pursuant to Article IV (as applicable). 
  

				
	 STAGE OF DEVELOPMENT
	  	MINIMUM
PAYMENT DUE
	upon filing the first IND for each Licensed Product with a distinct Licensed Compound in the Licensed Field	  	$	15,000
		
	completion of a Phase II Clinical Trial for each Licensed Product with a distinct Licensed Compound in the Licensed Field	  	$	50,000
		
	upon filing an NDA (but not an ANDA) for each Licensed Product with a distinct Licensed Compound in the Licensed Field	  	$	75,000
		
	upon the First Commercial Sale for each Licensed Product with a distinct Licensed Compound, based on an approved NDA (but not an ANDA) in the Licensed Field.	  	$	150,000

 For the avoidance of doubt, the parties acknowledge and agree that in no event shall Licensee owe
University and/or Niigata payments under both this Article 3.8 and Article IV with respect to milestone payments received by Licensee from Sublicensees for the milestones listed hereunder. 
 In the event of default of any payment owing to University and/or Niigata under the terms of this Agreement, and if it becomes necessary for University
and/or Niigata to undertake legal action to collect said payment, Licensee shall pay all reasonable legal fees and costs incurred by University and/or Niigata in connection therewith. 
  

 10 

 EXECUTION COPY 
  

 3.9. The parties recognize that different Licensed Products may contain the same
Licensed Compound. However, the parties agree that only one milestone shall be payable pursuant to Section 3.8 or IV (as applicable) for each individual Licensed Compound, regardless of the number of Licensed Products containing such Licensed
Compound. For purposes of this Agreement, substitution of halogens, chalcogens, or differing lengths of a hydrocarbon backbone shall not be considered distinct Licensed Compounds. 
 3.10. Nothing in this Agreement shall be construed to require the payment of more than one royalty or percentage of Sublicense Income with
regard to the Net Sale of an individual Licensed Product in the Licensed Field. No multiple royalties or percentages of Sublicense Income shall be payable because any Licensed Product, or its manufacture, use, sale, offer for sale or importation is
covered by more than one Valid Claim in a given country. 
 IV. SUBLICENSES 
 In the case of income derived by Licensee from Sublicensees, Licensee shall pay University a share of Sublicense Income, whose share shall be in accordance with the following table, on a Sublicensee by Sublicensee
basis and on a Class of Licensed Compound by Class of Licensed Compound basis, subject to Article 3.8: 
  

			
	 STAGE OF DEVELOPMENT AT THE
TIME OF
 EXECUTING A SUBLICENSE AGREEMENT
WITH
 THE APPLICABLE SUBLICENSEE WITH 
 RESPECT TO THE APPLICABLE CLASS OF 
 LICENSED COMPOUND:
	  	 % OF SUBLICENSE INCOME RECEIVED

 FROM THE APPLICABLE SUBLICENSEE WITH 
 RESPECT TO THE APPLICABLE CLASS OF 
 LICENSED COMPOUND AND PAYABLE TO 
 UNIVERSITY:

	Prior to completion of a Phase II Clinical Trial for at least one Licensed Product in the Class of Licensed Compound in the Licensed Field	  	25%
		
	Following completion of a Phase II Clinical Trial for at least one Licensed Product in the Class of Licensed Compound in the Licensed Field	  	12.5%

 For the avoidance of doubt, the parties acknowledge and agree that: 
  

	 	(i)	 In the event that Licensee executes a sublicense agreement with respect to Class 1 with a Sublicensee prior to completion of a Phase II Clinical Trial for at least
one Licensed Product in Class 1, and also sublicenses Class 2 to the same 

  

 11 

 EXECUTION COPY 
  

	 	 
Sublicensee after completion of a Phase II Clinical Trial for a Licensed Product in Class 2, Licensee shall pay University 25% of Sublicense Income received
from such Sublicensee with respect to any Licensed Products in Class 1, and 12.5 % of Sublicense Income received from such Sublicensee with respect to any Licensed Products in Class 2. By way of further example for the avoidance of doubt,
in the event that Licensee executes a sublicense agreement with respect to Class 2 with a Sublicensee prior to completion of a Phase II Clinical Trial for at least one Licensed Product in Class 2, and also sublicenses Class 3 to the same Sublicensee
after completion of a Phase II Clinical Trial for a Licensed Product in Class 3, Licensee shall pay University 25% of Sublicense Income received from such Sublicensee with respect to any Licensed Products in Class 2, and 12.5 % of Sublicense
Income received from such Sublicensee with respect to any Licensed Products in Class 3; and 

  

	 	(ii)	In the event that Licensee executes a sublicense agreement with respect to Class 1 with a Sublicensee (“Sublicensee A”) prior to completion of a Phase II Clinical Trial
for at least one Licensed Product in Class 1, and later sublicenses Class 1 to another Sublicensee (“Sublicensee B”) after completion of a Phase II Clinical Trial for a Licensed Product in Class 1, Licensee shall pay University 25% of
Sublicense Income received from Sublicensee A with respect to any Licensed Products in Class 1, and 12.5 % of Sublicense Income received from Sublicensee B with respect to any Licensed Products in Class 1. By way of further example for the
avoidance of doubt, in the event that Licensee executes a sublicense agreement with respect to Class 2 with a Sublicensee (“Sublicensee C”) prior to completion of a Phase II Clinical Trial for at least one Licensed Product in Class 2, and
later sublicenses Class 2 to another Sublicensee (“Sublicensee D”) after completion of a Phase II Clinical Trial for a Licensed Product in Class 2, Licensee shall pay University 25% of Sublicense Income received from Sublicensee C with
respect to any Licensed Products in Class 2, and 12.5 % of Sublicense Income received from Sublicensee D with respect to any Licensed Products in Class 2. 

 Notwithstanding the foregoing, in the event that Licensee executes a sublicense agreement with
respect to Class 2, Licensee shall pay University two-third ( 2/3) of the Sublicense Income otherwise payable to University
under this Article IV, and Licensee shall pay Niigata the remaining one-third ( 1/3) of such Sublicense Income, provided,
however, that (a) in the event any such Sublicense Income is compensation specifically and solely for the sublicensing of the Niigata Patents (as opposed to the Niigata Patents and the other Patents within Class 2), then Licensee shall pay
University one-half ( 1/2) of the Sublicense Income otherwise payable to University under this Article IV, and Licensee
shall pay Niigata the remaining one-half ( 1/2) of such Sublicense Income; (b) in the event any such Sublicense Income
is compensation specifically and solely for the sublicensing of the Niigata Technology, then Licensee shall pay Niigata one hundred percent (100%) of such Sublicense Income; and (c) in the event any such Sublicense Income is compensation
specifically and solely for the sublicensing of (i) Patents other than the Niigata Patents or (ii) University Technology, then Licensee shall pay University one hundred percent (100%) of such Sublicense Income. 

  

 12 

 EXECUTION COPY 
  

 No later than thirty (30) days before payments are due hereunder, Licensee retains the right to
notify University and Niigata in writing of its determination of the allocation of payments between University and Niigata hereunder (if any). In such an event, University and Niigata shall have thirty (30) days to respond in writing if they
disagree with Licensee’s determination. In the event Licensee does not receive written notice of a disagreement within such 30 day period, then Licensee’s determination shall be deemed acceptable to the parties. In the event Licensee
receives written notice of a disagreement within such 30 day period, Licensee retains the right to make Sublicense Income payments into an escrow account until such time as University and Niigata provide Licensee with written confirmation of their
resolution of such disagreement. In no event shall Licensee owe University and Niigata, in the aggregate, Sublicense Income payments greater than the amounts set forth in the table herein. 
 V. COMMERCIALLY REASONABLE EFFORTS 
 5.1.
Licensee shall use commercially reasonable efforts to proceed diligently with the development, manufacture and sale of at least one (1) Licensed Product either directly or through a Sublicensee in each Class of Licensed Compounds, and shall
earnestly and diligently offer and continue to offer for sale upon NDA approval, at least one (1) Licensed Product in each Class of Licensed Compounds under reasonable conditions during the Term of this Agreement either directly or through a
Sublicensee. 
 In particular, Licensee or its Sublicensee(s) will use commercially reasonable efforts to meet the Performance Milestones,
which such achievement shall be conclusive evidence that Licensee has used commercially reasonable efforts as required in the preceding paragraph. In the event that Licensee fails to meet a particular Performance Milestone for a particular Class of
Licensed Compounds during the timeframe set forth in Appendix C, University shall have the right to terminate the licenses granted hereunder to University’s rights for that particular Class of Licensed Compounds, upon thirty (30) days
advance written notice to Licensee, unless Licensee either (i) cures such breach within such thirty (30) day period, or (ii) elects to extend the Performance Milestone deadline pursuant to the provisions of Section 5.2 below.

 5.2. Licensee may have an additional six (6) months to reach a Performance Milestone upon payment of $20,000 to
University, and in addition, if the Performance Milestone is not met with respect to a Class 2 Licensed Compound, $10,000 to Niigata. In such an event, the timeframes for the applicable Performance Milestone and all remaining outstanding Performance
Milestones set forth in Appendix C shall be extended by six (6) months. Up to two (2) extensions, each requiring payment, may be obtained for any individual Performance Milestone for each Class of Licensed Compounds, however, and
notwithstanding the provisions of Section 7.1 only three (3) total extensions may be obtained under Appendix C for each Class of Licensed Compounds. 
 If Licensee exhausts all extensions as set forth in the preceding paragraph of this Article 5.2, and still has not met the obligations outlined in Appendix C (as extended), University may terminate this Agreement
with respect to such Class of Licensed Compounds upon thirty (30) days written notice to Licensee, unless Licensee cures such breach within such thirty (30) day period. 
  

 13 

 EXECUTION COPY 
  

 VI. DISCLOSURE AND CONFIDENTIALITY 
 6.1. Confidential Information disclosed by one party (“Disclosing Party”) to the other party (“Receiving Party”) may
be oral or in writing, provided that any information disclosed orally shall be reduced to writing within thirty (30) days of disclosure and all such information shall be clearly marked “CONFIDENTIAL” on the first page of such written
disclosure. 
 6.2. Receiving Party agrees that all Confidential Information received under this Agreement or the Original
Agreement shall be maintained in confidence during the Term and for a period of five (5) years from the expiration or termination date of this Agreement and further agrees not to use such Confidential Information for any purpose other than
fulfilling the purposes and upholding the obligations of this Agreement without the prior written consent of Disclosing Party. Receiving Party shall use the same standard of care to protect the confidentiality of Confidential Information received
under this Agreement as it uses to protect its own Confidential Information, and shall limit disclosure of Disclosing Party’s Confidential Information to those of its employees, agents, consultants, investors and potential investors,
Sublicensees, potential sublicensees and collaborators who have an actual need to know such information and who have a written obligation, or are subject to applicable University policies, to protect the confidentiality of such Confidential
Information which is at least as protective of such information as the agreement contained herein. 
 6.3. Notwithstanding
Articles 2 or 6.2, the obligations of the Receiving Party regarding confidentiality and use of University Technology or Niigata Technology or Confidential Information disclosed hereunder shall not include: 
 (i) information which, at the time of disclosure, was published, known publicly, or otherwise in the public domain; 
 (ii) information which, after disclosure, is published, becomes known publicly, or otherwise becomes part of the public domain through no
fault of the Receiving Party; 
 (iii) information which the Receiving Party can establish was in its possession prior to the
time of disclosure; 
 (iv) information which, after disclosure, is made available to Receiving Party in good faith by a third
party under no obligation of confidentiality to the Disclosing Party; or information which either party is required to disclose to comply with applicable laws or regulations, or with a court or administrative order, provided that the Disclosing
Party receives prior written notice of such disclosure and that the Receiving Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure and, if possible, to minimize the extent of such disclose. 

 

 14 

 EXECUTION COPY 
  

 6.4 For the avoidance of doubt, the parties acknowledge and agree that Niigata is
bound by the provisions of this Article VI with respect to disclosures made by Licensee and/or University prior to the Effective Date and thereafter during the term of the License Agreement, including without limitation, discussions relating to the
Niigata Patents and their prosecution, and the negotiation of this Agreement. 
 VII. CANCELLATION OR TERMINATION 
 7.1. It is expressly agreed that, if Licensee should fail to deliver to University any payment, royalty, or equity at the time or times
that the same should be due to University or if Licensee should in any material respect violate or fail to keep or perform any covenant, condition, or undertaking of this Agreement on its part to be kept or performed hereunder (but specifically
excluding any diligence obligations under Article V), then the University, by written notice to Licensee, shall have the right to terminate this Agreement, provided, however, that Licensee shall have the opportunity to cure any such breach described
in University’s written notice within thirty (30) days of receipt. Licensee’s right to cure a breach after the first two breaches of Licensee properly noticed by University under the terms of this Agreement (regardless of the nature
of those breaches) shall be conditioned upon Licensee paying the reasonable costs and expenses of University directly relating to such breach by Licensee. If University should in any material respect violate or fail to keep or perform any material
covenant, condition, or undertaking of this Agreement on its part to be kept or performed hereunder, then Licensee, by written notice to University, shall have the right to terminate this Agreement, provided, however, that University shall have the
opportunity to cure any such breach described in Licensee’s notice within thirty (30) days of receipt. 
 7.2.
University may terminate this Agreement with respect to a Class of Licensed Compounds or in whole for Licensee’s lack of diligence, pursuant to the provisions of Articles 5.1, 5.2 or 5.3 of this Agreement, as the case may be. 
 7.3. If Licensee should be adjudged bankrupt or enter into a composition with or assignment to its creditors, then in such event
University shall have the right to cancel and terminate this Agreement, and the license herein provided for, by written notice to Licensee. 
 7.4. Any termination or cancellation under any provision of this Agreement shall not relieve either party of any obligation which accrued prior to the effective date of such termination, including, in the case of
Licensee, its obligation to pay any royalty or other fees (including attorney’s fees pursuant to Article 3.2 hereof) due or owing at the time of such cancellation or termination. 
 7.5. Licensee may terminate this Agreement at any time by providing University and Niigata with thirty (30) days advance written
notice. 
 VIII. RIGHTS UPON CANCELLATION OR TERMINATION 
 The parties acknowledge and agree that upon the termination or expiration of this Agreement for any reason: (i) each party retains all right, title, and interest in such party’s inventions and intellectual property, including,
without limitation, its share of 

  

 15 

 EXECUTION COPY 
  

 
any joint inventions and jointly owned Patents, and (ii) each of the owning parties may commercially exploit any jointly owned inventions and jointly
owned Patents in any countries without any further accounting to the other party(ies). 
 IX. USE OF OTHER PARTY’S NAME 
 The use of the name of a party by any other party, or any contraction thereof, in any manner in connection with this license is expressly prohibited
except with the prior written consent of such party. 
 X. UNIVERSITY USE 
 It is expressly agreed that, notwithstanding any other provisions herein, University is free to use University Technology, Patents and Licensed Compounds for its own non-commercial research, and clinical, teaching and
educational purposes (including distribution of any compounds covered under the Patents to academic collaborators provided that the academic collaborators receiving Licensed Compounds shall be obligated to not transfer the Licensed Compounds to
third party commercial entities and to not use the Licensed Compounds in research sponsored by third party commercial entities) without payment of royalties. In no event shall University transfer the Patents or Licensed Compounds for sale or other
distribution to third parties other than non-profit research or educational institutions, or to such institutions in contravention of the foregoing provisions. Furthermore, except as otherwise set forth in the Sponsored Research Agreement,
University shall be free to publish University Technology as it sees fit. Notwithstanding the foregoing, in no event shall University use, or grant any third party a right to use, any Patents and/or Licensed Compounds in the Licensed Field for
commercial purposes during the Term, including, without limitation, conducting sponsored research with any for-profit entity during the Term. 
 It is expressly agreed that, notwithstanding any other provisions herein, Niigata is free to use Niigata Technology, Niigata Patents and Licensed Compounds covered by such Niigata Technology or Niigata Patents solely for its own
non-commercial research, and clinical, teaching and educational purposes (including distribution of any compounds covered under the Niigata Patents to academic collaborators provided that the academic collaborators receiving such Licensed Compounds
shall be obligated to not transfer such Licensed Compounds to third party commercial entities and to not use such Licensed Compounds in research sponsored by third party commercial entities) without payment of royalties. In no event shall Niigata
transfer the Niigata Patents or Licensed Compounds covered by the Niigata Patents or Niigata Technology for sale or other distribution to third parties other than non-profit research or educational institutions, or to such institutions in
contravention of the foregoing provisions. Notwithstanding the foregoing, in no event shall Niigata use, or grant any third party a right to use, any Niigata Patents and/or Licensed Compounds covered by the Niigata Patents or Niigata Technology in
the Licensed Field for commercial purposes during the Term, including, without limitation, conducting sponsored research with any for-profit entity during the Term. 
  

 16 

 EXECUTION COPY 
  

 XI. PATENTS 
 11.1. Licensee shall bear the cost of preparing, filing, prosecuting, and maintaining all United States and foreign patent applications and issued patents included within the Patents, and any interferences related to
the Patents, at its sole cost and expense. Such preparation, filing, prosecution, and maintenance shall be by patent counsel mutually agreeable to both University and Licensee (and Niigata with respect to the Niigata Patents) (“Patent
Counsel”). As of the Effective Date, Patent Counsel has been designated as Sterne, Kessler, Goldstein & Fox P.L.L.C. Patents claiming joint inventions (as determined by inventorship under U.S. patent laws) shall be filed in the name of
University and Licensee (and Niigata with respect to the Niigata Patents). Patent Counsel will keep University and Licensee advised of the prosecution of such Patents by forwarding copies of all official correspondence, (including, but not limited
to, applications, office actions, responses, etc.) relating thereto to University and Licensee. 
 11.2. University and
Niigata (with respect to the Niigata Patents) will provide Patent Counsel and Licensee, in a timely manner, all information in its possession or control which is subject to the terms and conditions of this Agreement necessary or useful for the
preparation, filing and maintenance of the Patents. University and Niigata (with respect to the Niigata Patents) agrees to cooperate with Licensee and Patent Counsel to whatever extent is reasonable and necessary to prepare, file, prosecute, and
maintain the Patents, including agreeing to execute any and all documents to provide Licensee the benefits of the licenses granted herein. 
 11.3. If the production, sale or use of Licensed Products under this Agreement by Licensee results in any claim for patent infringement against Licensee, Licensee shall promptly notify the University thereof in
writing, setting forth the facts of such claim in reasonable detail. As between the parties to this Agreement, Licensee shall have the first and primary right and responsibility, at its own expense, to defend and control the defense of any such
claim against Licensee or its Sublicensees, by counsel of its own choice. It is understood that any settlement of such actions which will have a material adverse effect on the rights of University hereunder must be approved by University. Such
approval shall not be unreasonably withheld. University agrees to cooperate with Licensee in any reasonable manner deemed by Licensee to be necessary in defending any such action. Licensee shall reimburse University and Niigata each for any out of
pocket expenses incurred in providing such assistance. 
 11.4. In the event that any Patents are infringed or appear to be
infringed by a third party, Licensee shall have the primary right, but not the obligation, to institute, prosecute and control any action or proceeding with respect to such infringement, by counsel of its choice, including any declaratory judgment
action arising from such infringement or apparent infringement. 
 11.5. Notwithstanding the foregoing, and in
University’s sole discretion, University shall be entitled to participate, through counsel of its own choosing and at its sole cost and expense, in any legal action described in Articles 11.4 and 11.5 involving the Inventions, provided that
Licensee shall retain the right to control such actions unless Licensee has previously abandoned or 

  

 17 

 EXECUTION COPY 
  

 
elected not to proceed with such legal action. Nothing in the foregoing sections shall be construed in any way which would limit the authority of the
Attorney General of North Carolina. 
 XII. REPRESENTATIONS, WARRANTIES AND COVENANTS; WAIVER 
 12.1. The University and Niigata each represents, and covenants as follows: 
 (i) It has the full right, power, and authority to enter into this Agreement and to perform all of its obligations hereunder. 

(ii) The execution and delivery of this Agreement and the consummation of the transaction contemplated by this Agreement do not
violate, conflict with, or constitute a default under its Charter or the terms and provisions of any agreement or other instrument to which it is a party or by which it is bound, or any material order, award, judgment or decree to which it is a
party or by which it is bound, or any state or federal law governing its activities. 
 (iii) Upon execution and delivery,
this Agreement will constitute the legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms. 
 (iv) Subject in the case of the University to the rights held by the U.S. Government under Public Law 96-517, as amended, and the implementing regulations, and to any rights as may be held by the other parties to this
Agreement, it is the owner of all rights to the Niigata Technology or the University Technology (as applicable), and its share of the title and interest in the Niigata Patents and Licensed Compounds covered by the Niigata Patents, Niigata
Technology, and/or University Technology (as applicable). Subject to the aforementioned rights of the U.S. Government in the case of the University, it has the sole and complete authority to issue and grant to Licensee the exclusive license granted
hereunder, free and clear of any claims, liens, encumbrances or charges of any third party. 
 (v) As of the Effective Date,
it has no knowledge of any potential infringement action or claim relating to the Niigata Technology or Niigata Patents, or Licensed Compounds and Licensed Products covered by the Niigata Technology or Niigata Patents, and has no knowledge of any
infringement, or breach of any agreement or of any facts that might reasonably lead to any claim of infringement or breach of any agreement relating to any patent, patent right, patentable invention, patent application, trade secret or other
proprietary right of any third party relating to its use or ownership of the foregoing, or Licensee’s licenses hereunder. However, neither University nor Niigata has done any searching regarding possible or potential infringement actions or
claims. 
 (vi) It will promptly disclose, and cause its inventors to disclose, to designated patent counsel of Licensee all
information known to University, Niigata or their respective inventors (as the case may be) which is or could be material to the patentability, enforceability or validity of any application or patent included in the Niigata Patents and Licensed
Compounds and/or Licensed Products covered by the Niigata Patents. However, University or Niigata shall not be required to actively search for any potential prior art. 
  

 18 

 EXECUTION COPY 
  

 12.2. To the extent that rights granted by the University to Licensee under this
Agreement are subject to the requirements of Public Law 96-517, as amended, and its implementing regulations, the University agrees that it will take all steps within its power to retain title, to the fullest extent permitted by law, to the
University Technology and its share of the title to the Patents and Licensed Compounds in the United States and in any foreign country designated by Licensee for the duration of this license. 
 12.3. It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth
shall be deemed a waiver as to any subsequent and/or similar breach or default. 
 XIII. LICENSE RESTRICTIONS 
 It is agreed that, as set forth in and subject to Articles 7.1 and 7.2, the rights and privileges granted to Licensee are each and all expressly
conditioned upon the faithful performance on the part of the Licensee of every requirement herein contained, and that each of such conditions and requirements may be and the same are specific license restrictions. 
 XIV. ASSIGNMENTS 
 This Agreement is binding upon and shall
inure to the benefit of the parties and their successors and permitted assigns. This Agreement may not be assigned or otherwise transferred by Licensee to any entity without the written consent of University, which consent shall not be unreasonably
withheld; provided, however, that Licensee, without such consent, may assign its rights and obligations under this Agreement in connection with a merger, consolidation, or sale of substantially all of Licensee’s assets. 
 XV. INDEMNITY 
 15.1. Licensee agrees to
indemnify, hold harmless and defend University, its officers, employees, and agents and Niigata and its officers, employees and agents (the “Indemnitees”), against any and all claims, suits, losses, damage, costs, fees, and expenses
asserted by third parties, both government and private (collectively, “Claims”), resulting from or arising out of the exercise of this license provided, however, that such indemnification shall not apply to any Claims to the extent
directly attributable to (i) the negligent activities or intentional misconduct of any Indemnitee or (ii) the settlement of a claim, suit, action, or demand by the Indemnitees without the prior written approval of Licensee. 
 15.2. Any Indemnitee seeking indemnification hereunder shall provide Licensee with prompt written notice of any Claim for which
indemnification is sought under this Agreement. Licensee agrees, at its own expense, to provide attorneys reasonably acceptable to the Indemnitee(s) to defend against any such Claim. The Indemnitee seeking indemnification hereunder shall cooperate
fully with Licensee in such defense and will permit Licensee to conduct and control such defense and the disposition 

  

 19 

 EXECUTION COPY 
  

 
of such Claim (including all decisions relative to litigation, appeal, and settlement); provided, however, that such Indemnitee shall have the right to
retain its own counsel reasonably acceptable to Licensee, at the expense of Licensee, if representation of such Indemnitee by the counsel retained by Licensee would be inappropriate because of actual or potential differences in the interests of such
Indemnitee and any other party represented by such counsel. Nothing herein should be construed to abrogate the authority of the Attorney General of the State of North Carolina. 
 XVI. INSURANCE 
 Prior to initiating clinical trials, Licensee shall obtain, at its sole cost and expense,
with reputable insurance companies, general liability insurance and products liability insurance coverage in an amount reasonably sufficient to protect against liability under Article XV, above. The University shall have the right to ascertain from
time to time that such coverage exists. 
 XVII. INDEPENDENT CONTRACTOR STATUS 
 Neither party hereto is an agent of the other for any purpose. 
 XVIII. LATE PAYMENTS 
 In the event that any payment due hereunder is not made when due, the payment shall accrue interest
beginning on the tenth (10th) day following the due date thereof, calculated at the annual rate of the sum of (a) two and one-half percent
(2.5%) plus (b) the prime interest rate quoted by The Wall Street Journal on the date said payment was due. The interest shall be compounded on the last day of each calendar quarter provided, however, that in no event shall said annual
interest rate exceed the maximum legal interest rate for corporations. Each such royalty payment, when paid, shall be accompanied by all accrued interest. 
 XIX. WARRANTY DISCLAIMER 
 University and Niigata makes no warranties that any patent will issue on University Technology or patent
applications within the Patents. University and Niigata further makes no warranties, express or implied, as to any matter whatsoever, including, without limitation, the condition of any Inventions, Patents, Licensed Compounds or Licensed Products
that are the subject of this Agreement; or the merchantability or fitness for a particular purpose of any such Inventions, Licensed Compounds or Licensed Products. University and Niigata shall not be liable for any direct, consequential, or other
damages suffered by Licensee or any others resulting from the use of the Licensed Compounds, Licensed Products, or Patents. 
  

 20 

 EXECUTION COPY 
  

 XX. ACCOUNTING AND RECORDS 
 20.1. Licensee will keep complete, true and accurate books of account and records for the purpose of showing the derivation of all amounts
payable to University and Niigata under this Agreement. Such books and records will be kept at Licensee’s principal place of business for at least three (3) years following the end of the calendar quarter to which they pertain, and will be
open at all reasonable times for inspection by an independent accounting firm reasonably acceptable to Licensee for the purpose of verifying Licensee’s royalty statements, or Licensee’s compliance in other respects with this Agreement.
Such accountant shall disclose to the University only information relating to the accuracy of the records kept and the payments made, and shall be under a duty to keep confidential any other information obtained from such accounts and records.

 20.2. Such inspections shall be at the expense of University, unless a variation or error resulting from an underpayment to
University exceeding the lesser of (i) US $5,000, or (ii) 1% for any consecutive twelve (12) month period is discovered in the course of any such inspection, whereupon all costs relating thereto would be paid by Licensee. 

20.3. Licensee will promptly pay to University and Niigata the full amount of any underpayment, along with interest calculated at the
annual rate of the sum of (a) two and one-half percent (2.5%) plus (b) the prime interest rate quoted by The Wall Street Journal on the date said payment was due. The interest shall be compounded on the last day of each calendar
quarter provided, however, that in no event shall said annual interest rate exceed the maximum legal interest rate for corporations. 
 XXI. COMPLIANCE WITH
LAWS 
 In exercising its rights under this license, Licensee shall fully comply with the requirements of any and all applicable laws,
regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this license. Licensee further agrees to indemnify and hold University and Niigata harmless from and against any Claims which might be
imposed by reason of any asserted or established violation of any such laws, order, rules, and/or regulations, pursuant to the provisions of Article XV. 
 XXII. US MANUFACTURE 
 It is agreed that any Licensed Products sold in the United States shall be substantially manufactured in the
United States to the extent required by Public Law 96-517, as amended, and the implementing regulations. 
  

 21 

 EXECUTION COPY 
  

 XXIII. NOTICES 
 Any notice required or permitted to be given to the parties hereto shall be deemed to have been properly given if delivered in person or mailed by first-class certified mail to the other party at the appropriate address as set forth below
or to such other addresses as may be designated in writing by the parties from time to time during the Term of this Agreement. 
  

					
	 UNIVERSITY
	  	 LICENSEE
	  	 NIIGATA

	 Director
 Office of Technology Development
 The University of North Carolina at
 Chapel Hill
 CB #4105, 308 Bynum Hall
 Chapel Hill, NC 27599-4105
	  	 Alan W. Dunton, M.D.
 President and Chief
 Executive Officer
 Panacos Pharmaceuticals, Inc.
 209 Perry Parkway
 Gaithersburg, MD 20877
	  	 President
 Niigata University of
 Pharmacy and Applied
 Life Sciences
 5-13-2 Kamishin’Ei-cho
 Niigata 950-2081, Japan

 XXIV. GOVERNING LAW 
 This Agreement shall be interpreted and construed in accordance with the laws of the United States and of the State of North Carolina, without regard to principles of conflicts of law. All disputes, controversies and
claims arising out of or related to this Agreement not settled by the dispute resolutions procedures pursuant to Article XXVIII of this Agreement will be subject to the exclusive jurisdiction of the state or federal courts of North Carolina.

 XXV. COMPLETE AGREEMENT 
 It is understood and
agreed between University and Niigata and Licensee that this Agreement, together with the Appendixes constitutes the entire agreement, both written and oral, between the parties respecting the subject matter hereof, and that all prior agreements
respecting the subject matter hereof (including, without limitation, the Original Agreement pursuant to Article II), either written or oral, expressed or implied, shall be abrogated, cancelled, and are null and void and of no effect. 
 XXVI. SEVERABILITY 
 In the event that a court of competent
jurisdiction holds any provision of this Agreement to be invalid, such holding shall have no effect on the remaining provisions of this Agreement, and they shall continue in full force and effect. 
  

 22 

 EXECUTION COPY 
  

 XXVII. SURVIVAL OF TERMS 
 The provisions of Articles 2.1, III and IV (in each case, with respect to payment obligations accruing prior to the date of expiration or termination), 2.5, VI, 7.4, VIII, IX, XII, XV, XVI, XVII, XVIII (with respect
to payment obligations accruing prior to the date of expiration or termination), XIX, XX (with respect to payment obligations accruing prior to the date of expiration or termination), XXI, XXIII, XXIV and this Article XXVII shall survive the
expiration or termination of this Agreement. 
 XXVIII. DISPUTE RESOLUTION 
 All disputes between Licensee and Niigata (but not University) arising out of or related to this Agreement, whether before or after termination of this Agreement shall be resolved as follows: 
 (a) The parties shall, through their duly authorized representatives, attempt in good faith for thirty (30) days to resolve the
dispute. 
 (b) If the dispute can not be resolved by the parties within 30 days, the Chief Operating Officer of Licensee and
the President of Niigata (the “Appointed Representatives”) shall meet in person at a mutually acceptable time and location or by means of telephone or video conference within thirty (30) days to attempt to resolve the dispute.

 (c) If the matter remains unresolved within thirty (30) days after the meeting of the Appointed Representatives or if
the Appointed Representatives fail to meet within thirty (30) days, either party may initiate arbitration upon written notice to the other party, whereupon the parties agree to settle their dispute by binding arbitration under the Rules of the
International Chamber of Commerce. If the arbitration is initiated by Niigata, the legal place of arbitration shall be in North Carolina. If the arbitration is initiated by Licensee, the legal place of arbitration shall be in Japan. The language
used in the arbitral proceedings shall be English. The party against whom such binding arbitration is found shall bear all costs of such binding arbitration. 
 Notwithstanding the foregoing, Licensee and Niigata acknowledge and agree that the provisions of this Article shall not apply to any
dispute, controversy or claim: (i) seeking a temporary restraining order, preliminary injunction, permanent injunction or other equitable relief where such relief is reasonably required to protect its interests; (ii) for the collection of
undisputed amounts; and/or (iii) which can not be finally and completely resolved without the participation of University or any third party who is not bound by the provisions of this Article. Any such dispute, controversy or claim discussed in
the previous sentence shall be subject to Article XXIV of this Agreement. 
 [The remainder of this page is intentionally left blank.]

  

 23 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, both University and Licensee have executed this Agreement, in duplicate originals, by their
respective officers hereunto duly authorized, the day and year of last signature below. 
  

					
	THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	 		  	PANACOS PHARMACEUTICALS, INC.
			
	 /s/ Catherine Innes
	 		  	 /s/ Alan W. Dunton

	Cathy Innes	 		  	Alan W. Dunton, M.D.
	Director	 		  	President and Chief Executive Officer
			
	 NIIGATA UNIVERSITY OF PHARMACY AND
 APPLIED LIFE SCIENCES
	 		  	
			
	 /s/ Mikio Yamazaki
	 		  	
	Mikio Yamazaki	 		  	
	President	 		  	

  

 24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]